Capricor Therapeutics, Inc. (CAPR)
9.52
-0.72
(-7.03%)
USD |
NASDAQ |
Nov 13, 16:00
9.41
-0.11
(-1.16%)
After-Hours: 19:59
Capricor Therapeutics Enterprise Value : 489.99M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 489.99M |
| November 11, 2026 | 546.97M |
| November 10, 2026 | 410.34M |
| November 09, 2026 | 467.32M |
| November 06, 2026 | 417.90M |
| November 05, 2026 | 394.64M |
| November 04, 2026 | 413.25M |
| November 03, 2026 | 373.71M |
| November 02, 2026 | 315.58M |
| October 30, 2026 | 265.58M |
| October 29, 2026 | 280.11M |
| October 28, 2026 | 256.86M |
| October 27, 2026 | 249.30M |
| October 26, 2026 | 228.37M |
| October 23, 2026 | 239.41M |
| October 22, 2026 | 251.04M |
| October 21, 2026 | 236.51M |
| October 20, 2026 | 278.95M |
| October 19, 2026 | 281.27M |
| October 16, 2026 | 284.76M |
| October 15, 2026 | 317.32M |
| October 14, 2026 | 277.78M |
| October 13, 2026 | 294.65M |
| October 12, 2026 | 328.95M |
| October 09, 2026 | 349.88M |
| Date | Value |
|---|---|
| October 08, 2026 | 360.34M |
| October 07, 2026 | 365.57M |
| October 06, 2026 | 345.23M |
| October 05, 2026 | 346.97M |
| October 02, 2026 | 414.99M |
| October 01, 2026 | 414.41M |
| September 30, 2026 | 445.23M |
| September 29, 2026 | 351.10M |
| September 28, 2026 | 359.24M |
| September 25, 2026 | 338.90M |
| September 24, 2026 | 351.10M |
| September 23, 2026 | 356.92M |
| September 22, 2026 | 395.85M |
| September 21, 2026 | 370.28M |
| September 18, 2026 | 379.58M |
| September 17, 2026 | 400.50M |
| September 16, 2026 | 350.52M |
| September 15, 2026 | 350.52M |
| September 14, 2026 | 365.05M |
| September 11, 2026 | 339.48M |
| September 10, 2026 | 335.42M |
| September 09, 2026 | 355.17M |
| September 08, 2026 | 379.58M |
| September 04, 2026 | 399.34M |
| September 03, 2026 | 392.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ARS Pharmaceuticals, Inc. | 365.40M |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Regeneron Pharmaceuticals, Inc. | 91.75B |
| SELLAS Life Sciences Group, Inc. | 1.484B |
| Sionna Therapeutics, Inc. | -61.75M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.66M |
| Total Expenses (Quarterly) | 42.66M |
| EPS Diluted (Quarterly) | -0.7338 |
| Earnings Yield | -27.79% |
| Normalized Earnings Yield | -27.79 |